Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cell Therapy
Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem …
Posted: June 25, 2012 at 11:21 pm
SUNRISE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Kristin Comella, the company's Chief Science Officer presented at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan June 13 - 16, 2012. One of the world's premier stem cell research events, the ISSCR format includes international research and poster presentations from invited speakers, exceptional peer-to-peer learning and unparalleled networking opportunities.
Comella presented a poster on clinical applications of adipose or fat derived stem cells (ADSCs).
The ISSCR annual meeting serves as the largest forum for stem cell and regenerative medicine professionals from around the world. Through lectures, symposia, workshops, and events attendees experience innovative stem cell and regenerative medicine research, advances and what's on the horizon. The meeting features more than 1,000 abstracts, nearly 150 speakers and provides numerous networking and professional development opportunities and social events. For additional information, visit http://www.isscr.org.
Kristin Comella has over 14 years experience in corporate entities with expertise in regenerative medicine, training and education, research, product development and senior management including more than 10 years of cell culturing experience. She has made a significant contribution to Bioheart's product development, manufacturing and quality systems since she joined the company in September 2004.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended March 30, 2012.
Read the original here:
Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem ...
Posted in Stem Cell Therapy
Comments Off on Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem …
Parsing Geron’s Stem Cell Foray: A Nature Journal Commentary
Posted: June 24, 2012 at 3:59 pm
Why did Geron "fail" in its
much ballyhooed pursuit of the first-ever human embryonic stem cell
therapy?
Christopher Scott, senior
research scholar at Stanford, and Brady Huggett,
business editor of the journal Nature, took a crack at
answering that question in a commentary in the June edition of
Nature.
research scholar at Stanford, and Brady Huggett,
business editor of the journal Nature, took a crack at
answering that question in a commentary in the June edition of
Nature.
Following the sudden abandonment last
fall by Geron of its hESC business and the first-ever clinical trial
of an hESC therapy, Scott and Huggett scrutinized the history of the
company. The financial numbers were impressive. They wrote,
fall by Geron of its hESC business and the first-ever clinical trial
of an hESC therapy, Scott and Huggett scrutinized the history of the
company. The financial numbers were impressive. They wrote,
"How did Geron’s R&D program
meet such a demise? After all, the company raised more than $583
million through 23 financings, including two venture rounds, and
plowed more than half a billion dollars into R&D (about half of
that into hESC work) through 2010.
"There are problems with being at
the forefront of unknown territory. Of Geron’s development efforts,
the hESC trial was the most prominent, and fraught. Therapies based
on hESCs were new territory for the US Food and Drug
Administration (FDA), and it eyed Geron warily. The
investigational new drug application (IND), filed in 2008, was twice
put on clinical hold while more animal data were collected among
fears that nonmalignant tumors would result from stray hESCs that
escaped the purification process. Geron says it spent $45 million on
the application, and at 22,000 pages, it was reportedly the largest
the agency had ever received."
The California stem cell agency also
bet $25 million on the company just a few months before it pulled the
plug. Geron repaid all the CIRM money that it had used up to that point.
bet $25 million on the company just a few months before it pulled the
plug. Geron repaid all the CIRM money that it had used up to that point.
Geron suffered from a lack of revenue
despite its vaunted stem cell patent portfolio. Scott and Huggett
reported that Geron received only $69 million from 1992 to 2010 from
collaborations, license and royalties. At the same time losses were
huge – $111 million in 2010.
despite its vaunted stem cell patent portfolio. Scott and Huggett
reported that Geron received only $69 million from 1992 to 2010 from
collaborations, license and royalties. At the same time losses were
huge – $111 million in 2010.
The Nature article noted all of that
was occurring while other biotech companies – such as Isis
and Alnylam – found ample financial support, revenue and
success.
was occurring while other biotech companies – such as Isis
and Alnylam – found ample financial support, revenue and
success.
Scott's and Huggett's directed their
final comment to Advanced Cell Technology, now the only
company in the United States with a clinical trial involving a human
embryonic stem cell therapy.
final comment to Advanced Cell Technology, now the only
company in the United States with a clinical trial involving a human
embryonic stem cell therapy.
"Your technology may be
revolutionary, your team may be dedicated and you may believe. But it
does not matter if no one else will stand at your side."
Our take: The California stem cell
agency obviously has learned something from its dealings with Geron.
The company's hESC announcement was an unpleasant surprise, to put it
mildly, coming only about three months after CIRM signed the Geron
loan agreement. Today, however, the agency has embarked on more,
equally risky ventures with other biotech enterprises. Indeed, CIRM
is forging into areas that conventional investment shuns. It is all
part of mission approved by California voters in 2004.
agency obviously has learned something from its dealings with Geron.
The company's hESC announcement was an unpleasant surprise, to put it
mildly, coming only about three months after CIRM signed the Geron
loan agreement. Today, however, the agency has embarked on more,
equally risky ventures with other biotech enterprises. Indeed, CIRM
is forging into areas that conventional investment shuns. It is all
part of mission approved by California voters in 2004.
The dream of cures from human embryonic
stem cells or even adult stem cells is alluring. And CIRM is feeling
much justifiable pressure to engage industry more closely. All the
more reason for CIRM's executives and directors to maintain a steely
determination to terminate research programs that are spinning their
wheels and instead pursue efforts that are making significant
progress in commercializing research and attracting other investors.
stem cells or even adult stem cells is alluring. And CIRM is feeling
much justifiable pressure to engage industry more closely. All the
more reason for CIRM's executives and directors to maintain a steely
determination to terminate research programs that are spinning their
wheels and instead pursue efforts that are making significant
progress in commercializing research and attracting other investors.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Parsing Geron’s Stem Cell Foray: A Nature Journal Commentary
The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014
Posted: June 24, 2012 at 3:59 pm
The California stem cell agency's
leading efforts to find a cure for HIV – one tied to the famous "Berlin Patient" – received a plug today in a piece in the
state capital's largest circulation newspaper, The Sacramento Bee.
The article by David Lesher focused on
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
The Berlin Patient is Timothy Brown,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,
"The
possibility of curing a global pandemic like AIDS with funding from
the California bond is exactly the kind of exciting potential that
inspired voters to approve Proposition 71 by
a wide margin. But the HIV research is also a good example of the
challenge facing the state's stem cell agency
as it tries to show voters that they made a good investment.
“None
of the research under way will reach patients until long after the 10
years of funding by the ballot measure runs out. With the HIV
project, researchers hope to be in human trials by 2014, but it is
likely to be at least 10 years before they can show it might work in
humans. And in the case of a stem cell cure
for AIDS, it would be many years after that before a treatment is
widely available.”
Jeff
Sheehy, a prominent AIDS activist and a board member at the stem
cell agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Sheehy, a prominent AIDS activist and a board member at the stem
cell agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Lesher also wrote,
"Nobody
thought stem cells might
be used to cure HIV when the bond (funding for the stem cell agency)
passed. Far from the embryonic stem cell treatments
that inspired the ballot measure, the HIV research involves a new and
growing integration of stem cell and
genetic science."
Indeed,
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004.
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Posted in Stem Cells, Stem Cell Therapy
Comments Off on The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014
Parsing Geron's Stem Cell Foray: A Nature Journal Commentary
Posted: June 24, 2012 at 3:57 pm
Why did Geron "fail" in its
much ballyhooed pursuit of the first-ever human embryonic stem cell
therapy?
Christopher Scott, senior
research scholar at Stanford, and Brady Huggett,
business editor of the journal Nature, took a crack at
answering that question in a commentary in the June edition of
Nature.
research scholar at Stanford, and Brady Huggett,
business editor of the journal Nature, took a crack at
answering that question in a commentary in the June edition of
Nature.
Following the sudden abandonment last
fall by Geron of its hESC business and the first-ever clinical trial
of an hESC therapy, Scott and Huggett scrutinized the history of the
company. The financial numbers were impressive. They wrote,
fall by Geron of its hESC business and the first-ever clinical trial
of an hESC therapy, Scott and Huggett scrutinized the history of the
company. The financial numbers were impressive. They wrote,
"How did Geron’s R&D program
meet such a demise? After all, the company raised more than $583
million through 23 financings, including two venture rounds, and
plowed more than half a billion dollars into R&D (about half of
that into hESC work) through 2010.
"There are problems with being at
the forefront of unknown territory. Of Geron’s development efforts,
the hESC trial was the most prominent, and fraught. Therapies based
on hESCs were new territory for the US Food and Drug
Administration (FDA), and it eyed Geron warily. The
investigational new drug application (IND), filed in 2008, was twice
put on clinical hold while more animal data were collected among
fears that nonmalignant tumors would result from stray hESCs that
escaped the purification process. Geron says it spent $45 million on
the application, and at 22,000 pages, it was reportedly the largest
the agency had ever received."
The California stem cell agency also
bet $25 million on the company just a few months before it pulled the
plug. Geron repaid all the CIRM money that it had used up to that point.
bet $25 million on the company just a few months before it pulled the
plug. Geron repaid all the CIRM money that it had used up to that point.
Geron suffered from a lack of revenue
despite its vaunted stem cell patent portfolio. Scott and Huggett
reported that Geron received only $69 million from 1992 to 2010 from
collaborations, license and royalties. At the same time losses were
huge – $111 million in 2010.
despite its vaunted stem cell patent portfolio. Scott and Huggett
reported that Geron received only $69 million from 1992 to 2010 from
collaborations, license and royalties. At the same time losses were
huge – $111 million in 2010.
The Nature article noted all of that
was occurring while other biotech companies – such as Isis
and Alnylam – found ample financial support, revenue and
success.
was occurring while other biotech companies – such as Isis
and Alnylam – found ample financial support, revenue and
success.
Scott's and Huggett's directed their
final comment to Advanced Cell Technology, now the only
company in the United States with a clinical trial involving a human
embryonic stem cell therapy.
final comment to Advanced Cell Technology, now the only
company in the United States with a clinical trial involving a human
embryonic stem cell therapy.
"Your technology may be
revolutionary, your team may be dedicated and you may believe. But it
does not matter if no one else will stand at your side."
Our take: The California stem cell
agency obviously has learned something from its dealings with Geron.
The company's hESC announcement was an unpleasant surprise, to put it
mildly, coming only about three months after CIRM signed the Geron
loan agreement. Today, however, the agency has embarked on more,
equally risky ventures with other biotech enterprises. Indeed, CIRM
is forging into areas that conventional investment shuns. It is all
part of mission approved by California voters in 2004.
agency obviously has learned something from its dealings with Geron.
The company's hESC announcement was an unpleasant surprise, to put it
mildly, coming only about three months after CIRM signed the Geron
loan agreement. Today, however, the agency has embarked on more,
equally risky ventures with other biotech enterprises. Indeed, CIRM
is forging into areas that conventional investment shuns. It is all
part of mission approved by California voters in 2004.
The dream of cures from human embryonic
stem cells or even adult stem cells is alluring. And CIRM is feeling
much justifiable pressure to engage industry more closely. All the
more reason for CIRM's executives and directors to maintain a steely
determination to terminate research programs that are spinning their
wheels and instead pursue efforts that are making significant
progress in commercializing research and attracting other investors.
stem cells or even adult stem cells is alluring. And CIRM is feeling
much justifiable pressure to engage industry more closely. All the
more reason for CIRM's executives and directors to maintain a steely
determination to terminate research programs that are spinning their
wheels and instead pursue efforts that are making significant
progress in commercializing research and attracting other investors.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Parsing Geron's Stem Cell Foray: A Nature Journal Commentary
The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014
Posted: June 24, 2012 at 3:56 pm
The California stem cell agency's
leading efforts to find a cure for HIV – one tied to the famous "Berlin Patient" – received a plug today in a piece in the
state capital's largest circulation newspaper, The Sacramento Bee.
The article by David Lesher focused on
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
The Berlin Patient is Timothy Brown,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,
"The
possibility of curing a global pandemic like AIDS with funding from
the California bond is exactly the kind of exciting potential that
inspired voters to approve Proposition 71 by
a wide margin. But the HIV research is also a good example of the
challenge facing the state's stem cell agency
as it tries to show voters that they made a good investment.
“None
of the research under way will reach patients until long after the 10
years of funding by the ballot measure runs out. With the HIV
project, researchers hope to be in human trials by 2014, but it is
likely to be at least 10 years before they can show it might work in
humans. And in the case of a stem cell cure
for AIDS, it would be many years after that before a treatment is
widely available.”
Jeff
Sheehy, a prominent AIDS activist and a board member at the stem
cell agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Sheehy, a prominent AIDS activist and a board member at the stem
cell agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Lesher also wrote,
"Nobody
thought stem cells might
be used to cure HIV when the bond (funding for the stem cell agency)
passed. Far from the embryonic stem cell treatments
that inspired the ballot measure, the HIV research involves a new and
growing integration of stem cell and
genetic science."
Indeed,
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004.
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Posted in Stem Cells, Stem Cell Therapy
Comments Off on The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014
Notre Dame establishes professorships in adult stem cell research
Posted: June 23, 2012 at 4:12 am
Public release date: 22-Jun-2012 [ | E-mail | Share ]
Contact: William Gilroy gilroy.6@nd.edu 574-631-4127 University of Notre Dame
Alumnus Michael Gallagher and his wife, Elizabeth, have made a $5 million gift to establish the Elizabeth and Michael Gallagher Family Professorships in Adult Stem Cell Research at the University of Notre Dame.
Their gift, which will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, will strengthen Notre Dame's leadership in the field of stem cell research and enhance the University's effective dialogue between the biomedical research community and the Catholic Church on matters related to the use and application of stem cells and regenerative medicine.
"As a Catholic university, Notre Dame carries a mantle of responsibility to use our scholarship and resources to help alleviate human suffering, and, in this area of research in particular, to do so with deep respect for the sanctity of all human life," said Rev. John I. Jenkins, C.S.C., the University's president. "These new professorships will enable us to effectively build upon an already strong foundation in this critically important field. We are tremendously grateful to the Gallaghers for making this possible with their transformative gift."
Despite years of research, there are no known cures for a large number of degenerative diseases, such as Type 1 diabetes, Parkinson's disease, cardiovascular disease, macular degeneration and spinal cord injuries. Stem cell research has the potential to contribute to the discovery of new and successful treatments for these and other diseases because it holds the unique promise of regenerating damaged cells and tissues, fully restoring tissues and organs to their normal function.
Although this vital area of research could accelerate the ability to alleviate much human suffering, it has generated extensive ethical debate with the use of embryonic versus non-embryonic stem cells. The Catholic Church affirms the dignity of all human life at every stage and vigorously opposes the destruction of human embryos for the harvesting of stem cells. At the same time, the Church strongly endorses the use of adult and non-embryonic stem cell research as a potential therapy for individuals suffering from these debilitating diseases. Research has demonstrated that adult stem cells, including all forms of non-embryonic stem cells, such as induced pluripotent stem cells and umbilical cord stem cells, can be harvested and programmed to achieve pluripotency the same characteristic that enables embryonic stem cells to differentiate into any type of cell.
An urgent need exists to increase the number of faculty experts performing adult stem cell research at Notre Dame. Doing so will expand upon the strong foundation the College of Science holds in these areas and will help create an environment for excellence in which faculty and students can learn, grow, collaborate and ultimately affect human health.
"We are overwhelmed with gratitude at the generous gift from Mike and Liz Gallagher," said Gregory P. Crawford, dean of the College of Science. "The impact of this gift is truly beyond measure. It will play a crucial role in attracting three more of the best faculty in the field of adult stem cell research to Notre Dame. Furthermore, this gift will equip our existing talented group of adult stem cell researchers at Notre Dame to take the next great leap toward ultimately forming a premier center in adult stem cell research."
Michael Gallagher is a 1991 graduate of Notre Dame, and his wife, Elizabeth, is a 1992 graduate of Saint Mary's College. They have two sons, Brock and Jack, and currently live near Denver.
Follow this link:
Notre Dame establishes professorships in adult stem cell research
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Notre Dame establishes professorships in adult stem cell research
Stem cell therapy in Hawaii going to the dogs
Posted: June 22, 2012 at 9:21 am
HAWAII KAI (HawaiiNewsNow) -
Cutting-edge technology is helping Hawaii's pets live better lives for months, even years. We were there as a beloved dog named Kumba received one of the first-ever, in-clinic stem cell therapy surgeries in the islands.
13 year old Kumba doesn't know he's a guinea pig. The Rottweiler-Lab mix is one of the first in Hawaii to undergo the stem cell procedure at Surf Paws in Hawaii Kai.
Kumba suffers severe arthritis in his hips and knees, doesn't eat much, and is even a bit depressed. "It's an effort for him to get up off the floor, and when he gets up and crosses the room, you can see the stiffness," says his owner, Rumi Hospodar.
Kumba's kids learn some of details of his surgery. Then, he's moved to a table and nods off from anesthesia. Once he's prepped, the procedure begins. The vet removes about two tablespoons of fat tissue from Kumba's shoulder. From there, the stem cells are separated from the fat and activated. Then, they're injected back into the affected areas.
The entire process takes four hours, but the dog is actually only under for about 20 minutes. Surf Paws used to send the tissue to the mainland for processing, but with technology from Medi-Vet America, they can do it all here.
"The patient had to be, you know, go home and come back a few days later and the timing was a little bit difficult. Now, everything is same day," says Surf Paws veterinarian Dr. Cristina Miliaresis.
Cost depends on the size of animal but can run up to $2,800. It's mainly done on dogs, cats, and horses who suffer osteoarthritis, hip dysplasia, ligament and cartilage damage, and other degenerative diseases. Their quality of life can improve within a couple of weeks.
Dr. Miliaresis says, "Some people might say, 'Oh, the dog's 13. Why are you doing this for a 13 year old dog? But even 6 months, pain-free, after a very, it's not simple, but it's a pretty straightforward procedure, to me (would be) just amazing."
The techs move all 97 pounds of Kumba to post-op - while his anxious owner looks on.
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Stem cell therapy in Hawaii going to the dogs
Stem cell therapy gives dog new lease on life
Posted: June 22, 2012 at 9:21 am
Stem cell therapy has gone to the dogs. The technology aimed at giving ailing pets a new lease on life has arrived in Hawaii.
13-year-old Kumba is still a bit dazed, coming out of general anesthesia. The veterinarian at Surf Paws Animal Hospital just extracted about two tablespoons of fat tissue from the dog. Stem cells from that fat tissue will then be used to help him with his arthritis.
"Once we get the stem cells then we do some extra processing steps to wake them up so that they're very active. At the end of that, the veterinarian will inject the stem cells into the areas of damage," says Carol Spangler Vaughn of Medivet America.
A company called MediVet America is bringing the technology to animal hospitals in Hawaii. This is a first for Oahu. The company says the procedure works on other animals with different types of ailments.
"So the nice thing about this we're not gonna give you a puppy back but we'll give you some nice quality time with your animal. You won't have to put them down because of their arthritis," Vaughn said.
Kumba's arthritis had gotten worse in the past five years, and his owners were wondering whether it was best to end his life to stop him from suffering.
'When we start saying things like oh we don't know how much longer, poor Kumba, he must be in a lot of pain. That kind of stuff really hits home especially since he's been with us for so long," said Rumi Hospodar Kumba's owner.
But with this new procedure, they're counting on Kumba to be pain free in a few weeks and are looking forward to get backdoing some of the things Kumba enjoyed, like swimming.
"He can't do that now since his joints are so bad, and he's getting so old so that's one of the many things I'm looking forward to," Kelsea Hopsodar, his other owner said.
The cost of the procedure runs from 24 to 28 hundred dollars, and it's covered by most pet insurance policies.
Originally posted here:
Stem cell therapy gives dog new lease on life
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Stem cell therapy gives dog new lease on life
‘Master molecule’ may improve stem cell treatment of heart attacks
Posted: June 21, 2012 at 7:10 pm
Public release date: 20-Jun-2012 [ | E-mail | Share ]
Contact: Phil Sneiderman prs@jhu.edu 443-287-9960 Johns Hopkins University
Johns Hopkins researchers have discovered that a single protein molecule may hold the key to turning cardiac stem cells into blood vessels or muscle tissue, a finding that may lead to better ways to treat heart attack patients.
Human heart tissue does not heal well after a heart attack, instead forming debilitating scars. For reasons not completely understood, however, stem cells can assist in this repair process by turning into the cells that make up healthy heart tissue, including heart muscle and blood vessels. Recently, doctors elsewhere have reported promising early results in the use of cardiac stem cells to curb the formation of unhealthy scar tissue after a heart attack. But the discovery of a "master molecule" that guides the destiny of these stem cells could result in even more effective treatments for heart patients, the Johns Hopkins researchers say.
In a study published in the June 5 online edition of the journal Science Signaling, the team reported that tinkering with a protein molecule called p190RhoGAP shaped the development of cardiac stem cells, prodding them to become the building blocks for either blood vessels or heart muscle. The team members said that by altering levels of this protein, they were able to affect the future of these stem cells.
"In biology, finding a central regulator like this is like finding a pot of gold," said Andre Levchenko, a biomedical engineering professor and member of the Johns Hopkins Institute for Cell Engineering, who supervised the research effort.
The lead author of the journal article, Kshitiz, a postdoctoral fellow who uses only his first name, said, "Our findings greatly enhance our understanding of stem cell biology and suggest innovative new ways to control the behavior of cardiac stem cells before and after they are transplanted into a patient. This discovery could significantly change the way stem cell therapy is administered in heart patients."
Earlier this year, a medical team at Cedars-Sinai Medical Center in Los Angeles reported initial success in reducing scar tissue in heart attack patients after harvesting some of the patient's own cardiac stem cells, growing more of these cells in a lab and transfusing them back into the patient.
Using the stem cells from the patient's own heart prevented the rejection problems that often occur when tissue is transplanted from another person.
Levchenko's team wanted to figure out what, at the molecular level, causes the stem cells to change into helpful heart tissue. If they could solve this mystery, the researchers hoped the cardiac stem cell technique used by the Los Angeles doctors could be altered to yield even better results.
Original post:
'Master molecule' may improve stem cell treatment of heart attacks
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on ‘Master molecule’ may improve stem cell treatment of heart attacks
Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters
Posted: June 21, 2012 at 7:15 am
The leading international family stem cell bank, Cryo-Save, celebrates the grand opening of its brand new headquarters office in Zutphen, the Netherlands, by honoring PhD. T.H.J. Nijhuis with the Young Investigator Award on June 22nd.
Cryo-Save`s headquarters, located in Zutphen, the Netherlands, is celebrating the grand opening of its brand new, fully-renovated headquarters. On June 22nd, Arnoud van Tulder, CEO of Cryo-Save, and attorney-at-law C. Bieze, deputy in the province of Gelderland, will officially open the company`s new global headquarters office.
To mark the occasion, the company will grant PhD. T.H.J. Nijhuis, winner of the Cryo-Save Young Investigator Award, a prize of 5,000 euros. Mr. Nijhuis has focused his most recent research on umbilical cord mesenchymal stem cells and pursues his work at the Erasmus Medical Center, part of the Erasmus University of Rotterdam, the Netherlands.
Arnoud van Tulder, CEO of Cryo-Save, says "We are proud to name Mr. T.H.J. Nijhuis, as the winner of the Cryo-Save Young Investigator Award. Research is a cornerstone of the stem cell industry, and it`s advancements like that of Mr. T.H.J. Nijhuis that makes us so optimistic for the future."
As part of Cryo-Save`s educational and community outreach efforts, the Cryo-Save Young Investigator Award is yet another example of how the company supports the advancement of stem cell use in the medical field. Cryo-Save seeks to improve and expand stem cell knowledge among the general public and professional health community, as they see in stem cell therapy a huge potential in the treatment of various diseases.
More information:
Ccile Kastler - Communications Manager
cecile.kastler@cryo-save.com - tel. +41-(0) 79 827 80 98
Cryo-Save: http://www.cryo-save.com/group
Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on 3 continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and South Africa.
Follow this link:
Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters
Posted in Stem Cell Therapy
Comments Off on Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters